343 related articles for article (PubMed ID: 16224817)
61. Resistance to natural killer cell lysis conferred by TAP1/2 genes in human antigen-processing mutant cells.
Salcedo M; Momburg F; Hämmerling GJ; Ljunggren HG
J Immunol; 1994 Feb; 152(4):1702-8. PubMed ID: 8120379
[TBL] [Abstract][Full Text] [Related]
62. TAP-independent MHC class I peptide antigen presentation to alloreactive CTL is enhanced by target cell incubation at subphysiologic temperatures.
Shi Y; Smith KD; Lutz CT
J Immunol; 1998 May; 160(9):4305-12. PubMed ID: 9574533
[TBL] [Abstract][Full Text] [Related]
63. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
[TBL] [Abstract][Full Text] [Related]
64. B and T lymphocyte attenuator is highly expressed on CMV-specific T cells during infection and regulates their function.
Serriari NE; Gondois-Rey F; Guillaume Y; Remmerswaal EB; Pastor S; Messal N; Truneh A; Hirsch I; van Lier RA; Olive D
J Immunol; 2010 Sep; 185(6):3140-8. PubMed ID: 20693422
[TBL] [Abstract][Full Text] [Related]
65. Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes.
Kaka AS; Shaffer DR; Hartmaier R; Leen AM; Lu A; Bear A; Rooney CM; Foster AE
J Immunother; 2009 Sep; 32(7):726-36. PubMed ID: 19561536
[TBL] [Abstract][Full Text] [Related]
66. Preferential HLA usage in the influenza virus-specific CTL response.
Boon AC; De Mutsert G; Fouchier RA; Sintnicolaas K; Osterhaus AD; Rimmelzwaan GF
J Immunol; 2004 Apr; 172(7):4435-43. PubMed ID: 15034059
[TBL] [Abstract][Full Text] [Related]
67. Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes.
Longmate J; York J; La Rosa C; Krishnan R; Zhang M; Senitzer D; Diamond DJ
Immunogenetics; 2001; 52(3-4):165-73. PubMed ID: 11220618
[TBL] [Abstract][Full Text] [Related]
68. Multiple Chlamydia pneumoniae antigens prime CD8+ Tc1 responses that inhibit intracellular growth of this vacuolar pathogen.
Wizel B; Starcher BC; Samten B; Chroneos Z; Barnes PF; Dzuris J; Higashimoto Y; Appella E; Sette A
J Immunol; 2002 Sep; 169(5):2524-35. PubMed ID: 12193722
[TBL] [Abstract][Full Text] [Related]
69. Presentation of an immunodominant immediate-early CD8+ T cell epitope resists human cytomegalovirus immunoevasion.
Ameres S; Mautner J; Schlott F; Neuenhahn M; Busch DH; Plachter B; Moosmann A
PLoS Pathog; 2013; 9(5):e1003383. PubMed ID: 23717207
[TBL] [Abstract][Full Text] [Related]
70. Requirement for HLA-DR+ accessory cells in natural killing of cytomegalovirus-infected fibroblasts.
Bandyopadhyay S; Perussia B; Trinchieri G; Miller DS; Starr SE
J Exp Med; 1986 Jul; 164(1):180-95. PubMed ID: 3014033
[TBL] [Abstract][Full Text] [Related]
71. Promiscuous CTL recognition of viral epitopes on multiple human leukocyte antigens: biological validation of the proposed HLA A24 supertype.
Burrows SR; Elkington RA; Miles JJ; Green KJ; Walker S; Haryana SM; Moss DJ; Dunckley H; Burrows JM; Khanna R
J Immunol; 2003 Aug; 171(3):1407-12. PubMed ID: 12874232
[TBL] [Abstract][Full Text] [Related]
72. Characterization of High-Avidity Cytomegalovirus-Specific T Cells with Differential Tetramer Binding Coappearing after Allogeneic Stem Cell Transplantation.
Ogonek J; Verma K; Schultze-Florey C; Varanasi P; Luther S; Schweier P; Kühnau W; Göhring G; Dammann E; Stadler M; Ganser A; Koehl U; Koenecke C; Weissinger EM; Hambach L
J Immunol; 2017 Jul; 199(2):792-805. PubMed ID: 28630092
[TBL] [Abstract][Full Text] [Related]
73. NK cell activity during human cytomegalovirus infection is dominated by US2-11-mediated HLA class I down-regulation.
Falk CS; Mach M; Schendel DJ; Weiss EH; Hilgert I; Hahn G
J Immunol; 2002 Sep; 169(6):3257-66. PubMed ID: 12218145
[TBL] [Abstract][Full Text] [Related]
74. Differentiation of cytomegalovirus-specific CD8(+) T cells in healthy and immunosuppressed virus carriers.
Gamadia LE; Rentenaar RJ; Baars PA; Remmerswaal EB; Surachno S; Weel JF; Toebes M; Schumacher TN; ten Berge IJ; van Lier RA
Blood; 2001 Aug; 98(3):754-61. PubMed ID: 11468176
[TBL] [Abstract][Full Text] [Related]
75. Isolation and expansion of human cytomegalovirus- specific cytotoxic T lymphocytes using interferon-gamma secretion assay.
Bissinger AL; Rauser G; Hebart H; Frank F; Jahn G; Einsele H
Exp Hematol; 2002 Oct; 30(10):1178-84. PubMed ID: 12384149
[TBL] [Abstract][Full Text] [Related]
76. HLA-E-dependent presentation of Mtb-derived antigen to human CD8+ T cells.
Heinzel AS; Grotzke JE; Lines RA; Lewinsohn DA; McNabb AL; Streblow DN; Braud VM; Grieser HJ; Belisle JT; Lewinsohn DM
J Exp Med; 2002 Dec; 196(11):1473-81. PubMed ID: 12461082
[TBL] [Abstract][Full Text] [Related]
77. Generation of human cytomegalovirus-specific cytotoxic T-lymphocytes in a short-term culture.
Laubscher A; Bluestein HG; Spector SA; Zvaifler NJ
J Immunol Methods; 1988 May; 110(1):69-77. PubMed ID: 2836515
[TBL] [Abstract][Full Text] [Related]
78. Impaired CTL recognition of cells latently infected with Kaposi's sarcoma-associated herpes virus.
Brander C; Suscovich T; Lee Y; Nguyen PT; O'Connor P; Seebach J; Jones NG; van Gorder M; Walker BD; Scadden DT
J Immunol; 2000 Aug; 165(4):2077-83. PubMed ID: 10925292
[TBL] [Abstract][Full Text] [Related]
79. Proliferation requirements of cytomegalovirus-specific, effector-type human CD8+ T cells.
van Leeuwen EM; Gamadia LE; Baars PA; Remmerswaal EB; ten Berge IJ; van Lier RA
J Immunol; 2002 Nov; 169(10):5838-43. PubMed ID: 12421965
[TBL] [Abstract][Full Text] [Related]
80. Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele.
Papanicolaou GA; Latouche JB; Tan C; Dupont J; Stiles J; Pamer EG; Sadelain M
Blood; 2003 Oct; 102(7):2498-505. PubMed ID: 12805061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
